Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity

Obesity

Volumn 24, Issue 12, 2016, Pages 2544-2552

  Bekaert, Marlies ^a   Ouwens, D Margriet ^a,b,c   Hörbelt, Tina ^b,c   Van de Velde, Frederique ^a   Fahlbusch, Pia ^b,c   Herzfeld de Wiza, Daniella ^b,c   Van Nieuwenhove, Yves ^a   Calders, Patrick ^a   Praet, Marleen ^a   Hoorens, Anne ^a   Geerts, Anja ^a   Verhelst, Xavier ^a   Kaufman, Jean Marc ^a   Lapauw, Bruno ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CELL PROTEIN; CHEMERIN; GAMMA GLUTAMYLTRANSFERASE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OMENTIN PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 4; UNCLASSIFIED DRUG; ADIPOCYTOKINE; BIOLOGICAL MARKER; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; SIGNAL PEPTIDE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HOMEOSTASISC MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; INTRAABDOMINAL FAT; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADIPOKINES; BIOMARKERS; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SEVERITY OF ILLNESS INDEX;

EID: 84992411234     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21674     Document Type: Article

References (40)

1. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–1850.
2. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:5286–5296.
3. Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev 2016;17:68–80.
4. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci 2010;1212:1–19.
5. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009;94:3085–3088.
6. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198:977–985.
7. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009;58:2731–2740.
8. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:1253–1261.
9. Greulich S, Chen WJ, Maxhera B, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013;8:e59697.
10. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494–1505.
11. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009;50:185–197.
12. Ehrlund A, Mejhert N, Lorente-Cebrian S, et al. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab 2013;98:503–508.
13. Fuster JJ, Zuriaga MA, Ngo DT, et al. Noncanonical wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 2015;64:1235–1248.
14. Zeng G, Awan F, Otruba W, et al. Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology 2007;45:195–204.
15. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571–579.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
17. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–1351.
18. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004;36:165–173.
19. Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012;56:933–942.
20. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016;65:1062–1079.
21. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010;391:1005–1018.
22. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015;26:153–161.
23. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011;60:313–326.
24. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59:969–974.
25. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012;56:1145–1151.
26. Ouwens DM, Bekaert M, Lapauw B, et al. Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch Physiol Biochem 2012;118:135–138.
27. Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012;61:706–714.
28. Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010;95:2892–2896.
29. Docke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol 2013;169:547–557.
30. Wolfs MG, Gruben N, Rensen SS, et al. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes 2015;5:e146.
31. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol 2005;175:487–493.
32. Gruben N, Aparicio Vergara M, Kloosterhuis NJ, et al. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice. PLoS One 2014;9:e96345.
33. Luangsay S, Wittamer V, Bondue B, et al. Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol 2009;183:6489–6499.
34. Alfadda AA, Sallam RM, Chishti MA, et al. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol Cells 2012;33:591–596.
35. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655–1661.
36. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011;46:91–97.
37. Mahdi T, Hanzelmann S, Salehi A, et al. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab 2012;16:625–633.
38. Behari J, Yeh TH, Krauland L, et al. Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 2010;176:744–753.
39. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167–1174.
40. Kim D, Chung GE, Kwak MS, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:132–138.